Related Experiment Videos
Methyldopa-induced immune hemolytic anemia and chronic active hepatitis
Archives of Internal Medicine
|March 1, 1983
Summary
Methyldopa therapy can trigger immune hemolytic anemia and chronic active hepatitis. Drug cessation and corticosteroids resolved these autoimmune complications, suggesting methyldopa may impair immune regulation.
Area of Science:
- Immunology
- Hepatology
- Hematology
Background:
- Methyldopa is a commonly prescribed antihypertensive medication.
- Autoimmune complications are rare but serious adverse effects associated with methyldopa therapy.
Observation:
- A 76-year-old male patient developed immune hemolytic anemia and chronic active hepatitis concurrently.
- These conditions emerged after prolonged treatment with methyldopa.
Findings:
- Discontinuation of methyldopa and a short course of high-dose corticosteroids (prednisone) led to the resolution of both autoimmune complications.
- The findings suggest a potential role of methyldopa in suppressing T-suppressor lymphocyte function, which may facilitate the development of autoimmune diseases.
Implications:
- Methyldopa's potential to induce immune dysregulation warrants careful patient monitoring for autoimmune adverse effects.
- Understanding the mechanism of methyldopa-induced autoimmunity could inform the development of safer antihypertensive strategies.
- This case highlights the importance of considering drug-induced autoimmunity in patients presenting with unexplained hematologic and hepatic disorders.